Aclidinium Bromide Twice Daily for the Treatment of Chronic Obstructive Pulmonary Disease: A Review

  title={Aclidinium Bromide Twice Daily for the Treatment of Chronic Obstructive Pulmonary Disease: A Review},
  author={Paul W Jones},
  journal={Advances in Therapy},
  • Paul W Jones
  • Published 2 April 2013
  • Medicine
  • Advances in Therapy
The inhaled, long-acting muscarinic antagonist, aclidinium bromide, was indicated in July 2012 in Europe and the USA for the maintenance of bronchodilator treatment to relieve symptoms of chronic obstructive pulmonary disease (COPD) in adults. Although initially investigated as a once-daily agent, a lower than expected improvement in trough forced expiratory volume over 1 s prompted re-evaluation as a twice-daily (b.i.d.) regimen. The dose approved for use in Europe, 400 μg b.i.d., achieved… 
Aclidinium bromide for stable chronic obstructive pulmonary disease.
There was no difference between aclidinium and placebo in all-cause mortality (low quality) and number of patients with exacerbations requiring a short course of oral steroids or antibiotics, or both (moderate quality).
Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis
Aclidinium reduced the incidence of exacerbation-related hospitalizations and improved quality of life, COPD symptoms and pulmonary function, and was not associated with increased mortality.
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease
There are important questions concerning the use of LAMAs in the treatment of patients suffering from stable COPD that need conclusive answers, and fixed-dose combination formulations of both novel and established L AMAs with LABAs are being developed.
Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions
How the neurotransmitter acetylcholine itself contributes to inflammation, bronchoconstriction, and remodeling in asthma is discussed, providing a comprehensive review of the current known physiological benefits of LAMAs in respiratory disease.
Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study.
It is demonstrated that both aclidinium and glycopyrronium significantly reduce hyperinflation and dyspnoea in severe and very severe COPD patients and was the only able to reduce lung ventilation inhomogeneity.
Muscarinic Receptor Antagonists.
Treatment with muscarinic receptor antagonists is an effective bronchodilator therapy in COPD and also in asthmatic patients and further beneficial effects of SAMAs and LAMAs are seen when added to existing treatments, including LABAs, inhaled corticosteroids and phosphodiesterase 4 inhibitors.
Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives
A detailed overview of the efficacy and safety of LABA/LAMA FDCs in global and Asian COPD patients is envisaged to provide a better understanding of the benefits of these therapies and to inform healthcare providers and patients on their appropriate use.
Atomic absorption spectrometric method has been developed for determination of aclidinium bromide in its pure and pharmaceutical dosage form. The method was based on the ability of aclidinium bromide
Prevention of acute exacerbations of chronic obstructive pulmonary disease
Хроническая обструктивная болезнь легких (ХОБЛ) – прогрессирующее заболевание с неполностью об ратимой бронхиальной обструкцией, возникающее под воздействием различных факторов (основным из которых
Prevention Strategies for Exacerbations of Chronic Obstructive Pulmonary Disease
Цель обзора: рассмотреть этиологию, клинические последствия, средства профилактики и лечения обострений хронической обструктивной болезни легких (ХОБЛ). Основные положения. Как правило, ХОБЛ


Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
Aclidinium is effective and well tolerated in patients with moderate to severe chronic obstructive pulmonary disease and time to first moderate or severe COPD exacerbation is significantly delayed in ACCLAIM/COPD II.
Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN
Aclidinium 200 μg and 400 μg twice-daily provided statistically significant and clinically meaningful improvements in COPD symptoms in patients with moderate to severe COPD.
S51 Efficacy of Aclidinium Bromide Compared with Tiotropium and Placebo in Patients with Moderate to Severe COPD: A Phase IIIb Study
Aclidinium 400 µg BID provided significant 24-hour bronchodilatory symptom control and daily symptom improvement throughout the study, with numerically greater improvement in morning and night-time symptoms among aclid inium-treated patients.
P189 Reduced COPD Exacerbations Associated with Aclidinium Bromide Versus Placebo: A Pooled Analysis of Phase III Data
A pooled analysis provides evidence to support a reduction in moderate or severe COPD exacerbations with aclidinium 200 µg and 400 µg BID compared with placebo.
Long-term efficacy of twice-daily aclidinium bromide in COPD patients: A one-year study
Treatment with aclidinium 200 µg or 400 µg BID results in benefits in lung function and health status in COPD patients over 1 year, and both treatment groups showed clinically significant improvements in SGRQ Total score and improvements in EuroQoL parameters.
Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
Aclidinium bromide exhibited time-independent PK following dosing to steady state, indicating that similar concentration versus time profiles will occur after repeated administration at the same dose and frequency.
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study
Twice-daily aclidinium significantly improved bronchodilation, health status and dyspnoea, and was well tolerated in patients with COPD.
Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
In patients with COPD, aclidinium 400 μg bid compared with placebo provided clinically meaningful improvements in 24-h bronchodilation that generally were comparable to tiotropium 18 μg daily but with significant differences in favor of aclIDinium observed in the average nighttime period.
Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I)
Treatment of moderate-to-severe COPD patients with twice-daily aclidinium 200 μg and 400 μg was associated with significant improvements in bronchodilation, health status, and COPD symptoms and both doses were well tolerated and had safety profiles similar to placebo.
Twice-daily aclidinium bromide in COPD patients: A pooled analysis of lung function in the ACCORD-COPD I and ATTAIN trials
Both doses of aclidinium produced significant improvements in lung function in COPD patients, with the 400 µg dose being consistently more effective.